25 XP   0   0   10

TaiMed Biologics
Buy, Hold or Sell?

Let's analyse TaiMed Biologics together

PenkeI guess you are interested in TaiMed Biologics. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of TaiMed Biologics. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about TaiMed Biologics

I send you an email if I find something interesting about TaiMed Biologics.

Quick analysis of TaiMed Biologics (30 sec.)










What can you expect buying and holding a share of TaiMed Biologics? (30 sec.)

How much money do you get?

How much money do you get?
NT$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
NT$9.40
Expected worth in 1 year
NT$8.85
How sure are you?
17.9%

+ What do you gain per year?

Total Gains per Share
NT$-0.55
Return On Investment
-0.7%

For what price can you sell your share?

Current Price per Share
NT$83.00
Expected price per share
NT$76.30 - NT$87.50
How sure are you?
50%

1. Valuation of TaiMed Biologics (5 min.)




Live pricePrice per Share (EOD)

NT$83.00

Intrinsic Value Per Share

NT$22.77 - NT$27.91

Total Value Per Share

NT$32.17 - NT$37.31

2. Growth of TaiMed Biologics (5 min.)




Is TaiMed Biologics growing?

Current yearPrevious yearGrowGrow %
How rich?$78.7m$84.9m-$4.3m-5.4%

How much money is TaiMed Biologics making?

Current yearPrevious yearGrowGrow %
Making money-$1.4m-$2m$571.6k38.2%
Net Profit Margin-50.1%-104.9%--

How much money comes from the company's main activities?

3. Financial Health of TaiMed Biologics (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#416 / 1010

Most Revenue
#380 / 1010

Most Profit
#275 / 1010

Most Efficient
#529 / 1010

What can you expect buying and holding a share of TaiMed Biologics? (5 min.)

Welcome investor! TaiMed Biologics's management wants to use your money to grow the business. In return you get a share of TaiMed Biologics.

What can you expect buying and holding a share of TaiMed Biologics?

First you should know what it really means to hold a share of TaiMed Biologics. And how you can make/lose money.

Speculation

The Price per Share of TaiMed Biologics is NT$83.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of TaiMed Biologics.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in TaiMed Biologics, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is NT$9.40. Based on the TTM, the Book Value Change Per Share is NT$-0.14 per quarter. Based on the YOY, the Book Value Change Per Share is NT$-0.21 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is NT$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of TaiMed Biologics.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 NT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per Share
Usd Eps-0.010.0%0.000.0%-0.010.0%-0.010.0%-0.010.0%
Usd Book Value Change Per Share-0.010.0%0.000.0%-0.010.0%-0.010.0%0.010.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.010.0%0.000.0%-0.010.0%-0.010.0%0.010.0%
Usd Price Per Share2.52-2.83-1.99-2.81-4.22-
Price to Earnings Ratio-92.83--350.17--85.19--61.10--21.89-
Price-to-Total Gains Ratio-287.57-1,090.02--454.40-31.50--237.73-
Price to Book Ratio8.72-9.57-6.41-7.78-11.99-
Price-to-Total Gains Ratio-287.57-1,090.02--454.40-31.50--237.73-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.5481
Number of shares392
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.00-0.01
Usd Total Gains Per Share0.00-0.01
Gains per Quarter (392 shares)-1.64-3.34
Gains per Year (392 shares)-6.56-13.35
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-7-170-13-23
20-13-240-27-36
30-20-310-40-49
40-26-380-53-62
50-33-450-67-75
60-39-520-80-88
70-46-590-93-101
80-52-660-107-114
90-59-730-120-127
100-66-800-134-140

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%2.018.00.010.0%4.020.015.010.3%4.020.019.09.3%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%7.031.01.017.9%8.032.03.018.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.039.00.0%0.00.043.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%7.031.01.017.9%8.032.03.018.6%

Fundamentals of TaiMed Biologics

About TaiMed Biologics

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-365/TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.

Fundamental data was last updated by Penke on 2024-04-16 22:00:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of TaiMed Biologics.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit TaiMed Biologics earns for each NT$1 of revenue.

  • Above 10% is considered healthy but always compare TaiMed Biologics to the Biotechnology industry mean.
  • A Net Profit Margin of -38.1% means that NT$-0.38 for each NT$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of TaiMed Biologics:

  • The MRQ is -38.1%. The company is making a huge loss. -2
  • The TTM is -50.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-38.1%TTM-50.1%+12.0%
TTM-50.1%YOY-104.9%+54.8%
TTM-50.1%5Y-78.9%+28.9%
5Y-78.9%10Y-50.3%-28.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-38.1%-207.2%+169.1%
TTM-50.1%-216.8%+166.7%
YOY-104.9%-282.3%+177.4%
5Y-78.9%-436.8%+357.9%
10Y-50.3%-597.3%+547.0%
1.1.2. Return on Assets

Shows how efficient TaiMed Biologics is using its assets to generate profit.

  • Above 5% is considered healthy but always compare TaiMed Biologics to the Biotechnology industry mean.
  • -1.5% Return on Assets means that TaiMed Biologics generated NT$-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of TaiMed Biologics:

  • The MRQ is -1.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.5%TTM-1.2%-0.3%
TTM-1.2%YOY-1.5%+0.3%
TTM-1.2%5Y-1.8%+0.6%
5Y-1.8%10Y-1.1%-0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.5%-13.3%+11.8%
TTM-1.2%-12.8%+11.6%
YOY-1.5%-11.6%+10.1%
5Y-1.8%-13.8%+12.0%
10Y-1.1%-15.6%+14.5%
1.1.3. Return on Equity

Shows how efficient TaiMed Biologics is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare TaiMed Biologics to the Biotechnology industry mean.
  • -2.3% Return on Equity means TaiMed Biologics generated NT$-0.02 for each NT$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of TaiMed Biologics:

  • The MRQ is -2.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -1.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.3%TTM-1.9%-0.5%
TTM-1.9%YOY-2.4%+0.6%
TTM-1.9%5Y-2.7%+0.8%
5Y-2.7%10Y-1.6%-1.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.3%-16.9%+14.6%
TTM-1.9%-16.1%+14.2%
YOY-2.4%-14.9%+12.5%
5Y-2.7%-19.3%+16.6%
10Y-1.6%-20.1%+18.5%

1.2. Operating Efficiency of TaiMed Biologics.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient TaiMed Biologics is operating .

  • Measures how much profit TaiMed Biologics makes for each NT$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare TaiMed Biologics to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated NT$0.00  for each NT$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of TaiMed Biologics:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-15.7%+15.7%
TTM-15.7%YOY-90.3%+74.6%
TTM-15.7%5Y-68.3%+52.7%
5Y-68.3%10Y-51.3%-17.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM-15.7%-238.5%+222.8%
YOY-90.3%-288.4%+198.1%
5Y-68.3%-486.2%+417.9%
10Y-51.3%-628.4%+577.1%
1.2.2. Operating Ratio

Measures how efficient TaiMed Biologics is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.73 means that the operating costs are NT$1.73 for each NT$1 in net sales.

Let's take a look of the Operating Ratio trends of TaiMed Biologics:

  • The MRQ is 1.731. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.982. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.731TTM1.982-0.251
TTM1.982YOY2.584-0.602
TTM1.9825Y2.371-0.389
5Y2.37110Y1.540+0.831
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7313.235-1.504
TTM1.9823.310-1.328
YOY2.5843.838-1.254
5Y2.3715.679-3.308
10Y1.5407.823-6.283

1.3. Liquidity of TaiMed Biologics.

1.3. Liquidity
1.3.1. Current Ratio

Measures if TaiMed Biologics is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.96 means the company has NT$5.96 in assets for each NT$1 in short-term debts.

Let's take a look of the Current Ratio trends of TaiMed Biologics:

  • The MRQ is 5.957. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.296. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.957TTM6.296-0.339
TTM6.296YOY7.124-0.829
TTM6.2965Y8.269-1.974
5Y8.26910Y5.217+3.053
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.9573.863+2.094
TTM6.2964.169+2.127
YOY7.1245.337+1.787
5Y8.2696.122+2.147
10Y5.2176.434-1.217
1.3.2. Quick Ratio

Measures if TaiMed Biologics is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare TaiMed Biologics to the Biotechnology industry mean.
  • A Quick Ratio of 1.50 means the company can pay off NT$1.50 for each NT$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of TaiMed Biologics:

  • The MRQ is 1.498. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.528. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.498TTM1.528-0.030
TTM1.528YOY1.714-0.185
TTM1.5285Y2.866-1.337
5Y2.86610Y2.138+0.728
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4983.504-2.006
TTM1.5283.991-2.463
YOY1.7145.371-3.657
5Y2.8666.088-3.222
10Y2.1386.395-4.257

1.4. Solvency of TaiMed Biologics.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of TaiMed Biologics assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare TaiMed Biologics to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.34 means that TaiMed Biologics assets are financed with 34.1% credit (debt) and the remaining percentage (100% - 34.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of TaiMed Biologics:

  • The MRQ is 0.341. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.342. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.341TTM0.342-0.001
TTM0.342YOY0.376-0.034
TTM0.3425Y0.316+0.025
5Y0.31610Y0.188+0.128
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3410.339+0.002
TTM0.3420.337+0.005
YOY0.3760.271+0.105
5Y0.3160.368-0.052
10Y0.1880.388-0.200
1.4.2. Debt to Equity Ratio

Measures if TaiMed Biologics is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare TaiMed Biologics to the Biotechnology industry mean.
  • A Debt to Equity ratio of 51.7% means that company has NT$0.52 debt for each NT$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of TaiMed Biologics:

  • The MRQ is 0.517. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.519. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.517TTM0.519-0.002
TTM0.519YOY0.604-0.085
TTM0.5195Y0.474+0.045
5Y0.47410Y0.272+0.202
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5170.392+0.125
TTM0.5190.403+0.116
YOY0.6040.335+0.269
5Y0.4740.427+0.047
10Y0.2720.461-0.189

2. Market Valuation of TaiMed Biologics

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every NT$1 in earnings TaiMed Biologics generates.

  • Above 15 is considered overpriced but always compare TaiMed Biologics to the Biotechnology industry mean.
  • A PE ratio of -92.83 means the investor is paying NT$-92.83 for every NT$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of TaiMed Biologics:

  • The EOD is -93.964. Based on the earnings, the company is expensive. -2
  • The MRQ is -92.832. Based on the earnings, the company is expensive. -2
  • The TTM is -350.174. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-93.964MRQ-92.832-1.132
MRQ-92.832TTM-350.174+257.342
TTM-350.174YOY-85.185-264.989
TTM-350.1745Y-61.096-289.078
5Y-61.09610Y-21.885-39.211
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-93.964-2.300-91.664
MRQ-92.832-2.656-90.176
TTM-350.174-2.718-347.456
YOY-85.185-4.145-81.040
5Y-61.096-6.258-54.838
10Y-21.885-6.315-15.570
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of TaiMed Biologics:

  • The EOD is 211.686. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 209.136. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 293.102. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD211.686MRQ209.136+2.550
MRQ209.136TTM293.102-83.966
TTM293.102YOY-473.547+766.649
TTM293.1025Y-96.438+389.540
5Y-96.43810Y-52.370-44.068
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD211.686-2.974+214.660
MRQ209.136-3.306+212.442
TTM293.102-3.508+296.610
YOY-473.547-5.613-467.934
5Y-96.438-8.378-88.060
10Y-52.370-8.873-43.497
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of TaiMed Biologics is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 8.72 means the investor is paying NT$8.72 for each NT$1 in book value.

Let's take a look of the Price to Book Ratio trends of TaiMed Biologics:

  • The EOD is 8.830. Based on the equity, the company is overpriced. -1
  • The MRQ is 8.724. Based on the equity, the company is overpriced. -1
  • The TTM is 9.570. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD8.830MRQ8.724+0.106
MRQ8.724TTM9.570-0.847
TTM9.570YOY6.413+3.158
TTM9.5705Y7.782+1.789
5Y7.78210Y11.992-4.210
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD8.8301.914+6.916
MRQ8.7242.116+6.608
TTM9.5702.097+7.473
YOY6.4132.881+3.532
5Y7.7823.550+4.232
10Y11.9923.936+8.056
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of TaiMed Biologics compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.285-0.136-52%-0.207-27%-0.277-3%0.179-259%
Book Value Per Share--9.4009.617-2%10.133-7%11.687-20%12.453-25%
Current Ratio--5.9576.296-5%7.124-16%8.269-28%5.217+14%
Debt To Asset Ratio--0.3410.3420%0.376-9%0.316+8%0.188+81%
Debt To Equity Ratio--0.5170.5190%0.604-14%0.474+9%0.272+90%
Dividend Per Share----0%-0%-0%-0%
Eps---0.221-0.148-33%-0.247+12%-0.305+38%-0.187-16%
Free Cash Flow Per Share--0.098-0.029+130%-0.559+670%-0.411+520%-0.552+663%
Free Cash Flow To Equity Per Share--0.0980.007+1300%-0.368+475%-0.257+362%-0.404+512%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.615+63%
Intrinsic Value_10Y_max--27.906--------
Intrinsic Value_10Y_min--22.774--------
Intrinsic Value_1Y_max---0.501--------
Intrinsic Value_1Y_min---0.494--------
Intrinsic Value_3Y_max--1.008--------
Intrinsic Value_3Y_min--0.912--------
Intrinsic Value_5Y_max--5.546--------
Intrinsic Value_5Y_min--4.932--------
Market Cap22658917664.000+1%22385918656.00025143208636.800-11%17724460594.400+26%24988964197.280-10%37516293676.562-40%
Net Profit Margin---0.381-0.501+31%-1.049+175%-0.789+107%-0.503+32%
Operating Margin----0.1570%-0.9030%-0.6830%-0.5130%
Operating Ratio--1.7311.982-13%2.584-33%2.371-27%1.540+12%
Pb Ratio8.830+1%8.7249.570-9%6.413+36%7.782+12%11.992-27%
Pe Ratio-93.964-1%-92.832-350.174+277%-85.185-8%-61.096-34%-21.885-76%
Price Per Share83.000+1%82.00092.100-11%64.925+26%91.535-10%137.423-40%
Price To Free Cash Flow Ratio211.686+1%209.136293.102-29%-473.547+326%-96.438+146%-52.370+125%
Price To Total Gains Ratio-291.074-1%-287.5671090.018-126%-454.400+58%31.500-1013%-237.728-17%
Quick Ratio--1.4981.528-2%1.714-13%2.866-48%2.138-30%
Return On Assets---0.015-0.012-21%-0.015-4%-0.018+17%-0.011-29%
Return On Equity---0.023-0.019-21%-0.024+3%-0.027+13%-0.016-33%
Total Gains Per Share---0.285-0.136-52%-0.207-27%-0.277-3%0.179-259%
Usd Book Value--78778840.20080599035.525-2%84923767.550-7%97947976.995-20%104371788.144-25%
Usd Book Value Change Per Share---0.009-0.004-52%-0.006-27%-0.009-3%0.006-259%
Usd Book Value Per Share--0.2890.295-2%0.311-7%0.359-20%0.382-25%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.007-0.005-33%-0.008+12%-0.009+38%-0.006-16%
Usd Free Cash Flow--821532.000-243704.275+130%-4681527.425+670%-3447866.345+520%-2730004.585+432%
Usd Free Cash Flow Per Share--0.003-0.001+130%-0.017+670%-0.013+520%-0.017+663%
Usd Free Cash Flow To Equity Per Share--0.0030.000+1300%-0.011+475%-0.008+362%-0.012+512%
Usd Market Cap695628772.285+1%687247702.739771896505.150-11%544140940.248+26%767161200.856-10%1151750215.870-40%
Usd Price Per Share2.548+1%2.5172.827-11%1.993+26%2.810-10%4.219-40%
Usd Profit---1850780.200-1495166.750-19%-2066793.075+12%-2604879.650+41%-1589079.231-14%
Usd Revenue--4857200.5003774388.475+29%4321086.400+12%4444156.560+9%2477072.008+96%
Usd Total Gains Per Share---0.009-0.004-52%-0.006-27%-0.009-3%0.006-259%
 EOD+4 -4MRQTTM+13 -19YOY+19 -135Y+15 -1710Y+12 -21

3.2. Fundamental Score

Let's check the fundamental score of TaiMed Biologics based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-93.964
Price to Book Ratio (EOD)Between0-18.830
Net Profit Margin (MRQ)Greater than0-0.381
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.498
Current Ratio (MRQ)Greater than15.957
Debt to Asset Ratio (MRQ)Less than10.341
Debt to Equity Ratio (MRQ)Less than10.517
Return on Equity (MRQ)Greater than0.15-0.023
Return on Assets (MRQ)Greater than0.05-0.015
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of TaiMed Biologics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.603
Ma 20Greater thanMa 5088.410
Ma 50Greater thanMa 10093.017
Ma 100Greater thanMa 20088.938
OpenGreater thanClose83.500
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in TWD. All numbers in thousands.

Summary
Total Assets3,893,922
Total Liabilities1,327,836
Total Stockholder Equity2,566,086
 As reported
Total Liabilities 1,327,836
Total Stockholder Equity+ 2,566,086
Total Assets = 3,893,922

Assets

Total Assets3,893,922
Total Current Assets2,151,398
Long-term Assets1,742,524
Total Current Assets
Cash And Cash Equivalents 251,007
Short-term Investments 398,126
Net Receivables 142,887
Inventory 1,265,183
Other Current Assets 75,217
Total Current Assets  (as reported)2,151,398
Total Current Assets  (calculated)2,132,420
+/- 18,978
Long-term Assets
Property Plant Equipment 908,257
Intangible Assets 625,789
Long-term Assets Other 6,103
Long-term Assets  (as reported)1,742,524
Long-term Assets  (calculated)1,540,149
+/- 202,375

Liabilities & Shareholders' Equity

Total Current Liabilities361,172
Long-term Liabilities966,664
Total Stockholder Equity2,566,086
Total Current Liabilities
Short Long Term Debt 226,965
Accounts payable 13,497
Other Current Liabilities 3,548
Total Current Liabilities  (as reported)361,172
Total Current Liabilities  (calculated)244,010
+/- 117,162
Long-term Liabilities
Long term Debt 495,041
Capital Lease Obligations Min Short Term Debt28,849
Long-term Liabilities Other 920
Long-term Liabilities  (as reported)966,664
Long-term Liabilities  (calculated)524,810
+/- 441,854
Total Stockholder Equity
Total Stockholder Equity (as reported)2,566,086
Total Stockholder Equity (calculated)0
+/- 2,566,086
Other
Capital Stock2,530,097
Common Stock Shares Outstanding 256,673
Net Debt 470,999
Net Invested Capital 3,288,092
Net Working Capital 1,790,226
Property Plant and Equipment Gross 908,257



Balance Sheet

Currency in TWD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-06-302011-06-302010-06-30
> Total Assets 
1,183,092
947,558
774,668
828,642
828,642
714,718
714,718
0
1,987,026
1,880,696
1,812,843
1,762,913
1,660,895
4,926,437
4,926,279
4,873,170
4,842,897
4,801,776
4,845,045
4,874,761
4,650,975
4,502,962
4,918,937
5,213,743
4,845,328
4,791,039
4,696,210
4,988,198
4,934,295
4,730,760
5,000,539
5,359,061
5,218,185
5,196,323
5,014,957
4,868,619
4,807,206
4,610,730
4,735,204
4,474,794
4,450,068
4,101,112
4,040,230
4,016,067
4,001,750
3,893,922
3,893,9224,001,7504,016,0674,040,2304,101,1124,450,0684,474,7944,735,2044,610,7304,807,2064,868,6195,014,9575,196,3235,218,1855,359,0615,000,5394,730,7604,934,2954,988,1984,696,2104,791,0394,845,3285,213,7434,918,9374,502,9624,650,9754,874,7614,845,0454,801,7764,842,8974,873,1704,926,2794,926,4371,660,8951,762,9131,812,8431,880,6961,987,0260714,718714,718828,642828,642774,668947,5581,183,092
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,918,699
2,700,015
2,518,779
2,389,523
2,683,351
2,549,195
2,457,168
2,595,213
2,949,679
2,805,095
2,777,964
2,542,044
2,442,813
2,413,873
2,334,950
2,518,914
2,464,399
2,477,236
2,164,993
2,179,313
2,195,292
2,216,804
2,151,398
2,151,3982,216,8042,195,2922,179,3132,164,9932,477,2362,464,3992,518,9142,334,9502,413,8732,442,8132,542,0442,777,9642,805,0952,949,6792,595,2132,457,1682,549,1952,683,3512,389,5232,518,7792,700,0152,918,69900000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,196,127
917,224
586,093
512,580
471,060
850,462
352,934
280,245
640,251
394,811
572,090
514,029
573,369
536,972
551,618
480,750
320,409
338,553
274,110
225,905
357,180
265,311
251,007
251,007265,311357,180225,905274,110338,553320,409480,750551,618536,972573,369514,029572,090394,811640,251280,245352,934850,462471,060512,580586,093917,2241,196,12700000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,449,000
1,449,000
1,423,400
1,425,923
1,425,946
821,546
921,546
955,546
855,569
981,569
631,569
531,569
451,589
381,589
409,269
351,589
430,888
413,241
371,288
372,731
307,215
381,663
398,126
398,126381,663307,215372,731371,288413,241430,888351,589409,269381,589451,589531,569631,569981,569855,569955,546921,546821,5461,425,9461,425,9231,423,4001,449,0001,449,00000000000000000000000000
       Net Receivables 
5,085
5,281
12,294
3,834
3,834
3,643
3,643
0
5,177
6,504
6,920
14,345
15,564
19,441
18,137
16,977
11,581
10,725
10,313
5,069
4,450
23,219
15,384
50,937
100,541
122,009
105,042
111,470
180,784
230,899
256,758
301,799
232,191
288,608
224,519
224,007
327,984
193,193
165,258
206,997
217,237
123,732
196,360
148,438
173,273
142,887
142,887173,273148,438196,360123,732217,237206,997165,258193,193327,984224,007224,519288,608232,191301,799256,758230,899180,784111,470105,042122,009100,54150,93715,38423,2194,4505,06910,31310,72511,58116,97718,13719,44115,56414,3456,9206,5045,17703,6433,6433,8343,83412,2945,2815,085
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
182,090
215,515
221,733
380,551
329,451
660,567
670,393
876,036
1,014,933
1,038,467
1,150,386
1,259,567
1,252,110
1,189,985
1,164,748
1,177,324
1,514,273
1,472,395
1,505,725
1,389,246
1,380,627
1,355,791
1,346,482
1,265,183
1,265,1831,346,4821,355,7911,380,6271,389,2461,505,7251,472,3951,514,2731,177,3241,164,7481,189,9851,252,1101,259,5671,150,3861,038,4671,014,933876,036670,393660,567329,451380,551221,733215,515182,0900000000000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,306,687
2,304,847
2,385,100
2,273,592
2,405,326
2,409,382
2,413,090
2,418,359
2,472,913
2,425,806
2,393,333
2,275,780
2,216,290
2,010,395
1,972,832
1,936,119
1,860,917
1,820,775
1,784,946
1,742,524
1,742,5241,784,9461,820,7751,860,9171,936,1191,972,8322,010,3952,216,2902,275,7802,393,3332,425,8062,472,9132,418,3592,413,0902,409,3822,405,3262,273,5922,385,1002,304,8472,306,68700000000000000000000000000
       Property Plant Equipment 
6,040
4,729
5,473
4,034
4,034
3,171
3,171
0
7,175
16,214
15,552
16,798
15,937
15,995
15,895
15,030
16,287
19,266
23,729
48,989
102,516
315,088
343,940
827,951
866,578
863,184
940,730
961,845
1,033,462
940,318
935,406
1,022,356
1,061,364
1,064,619
1,051,213
1,036,898
1,023,146
1,010,627
997,529
984,281
970,707
957,735
943,642
930,022
919,807
908,257
908,257919,807930,022943,642957,735970,707984,281997,5291,010,6271,023,1461,036,8981,051,2131,064,6191,061,3641,022,356935,406940,3181,033,462961,845940,730863,184866,578827,951343,940315,088102,51648,98923,72919,26616,28715,03015,89515,99515,93716,79815,55216,2147,17503,1713,1714,0344,0345,4734,7296,040
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
700,397
499,118
462,534
432,305
414,356
335,904
249,361
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000249,361335,904414,356432,305462,534499,118700,39700000000000000000000000
       Intangible Assets 
202,313
164,573
118,910
334,844
334,844
334,834
334,834
0
333,344
333,344
333,344
333,344
333,344
333,344
333,344
333,344
333,344
336,569
349,550
349,550
349,550
349,550
674,063
660,417
656,332
642,281
632,101
621,970
763,154
739,446
995,874
972,868
973,828
940,157
915,831
891,247
870,144
821,330
797,970
773,488
749,170
724,377
699,694
675,143
650,654
625,789
625,789650,654675,143699,694724,377749,170773,488797,970821,330870,144891,247915,831940,157973,828972,868995,874739,446763,154621,970632,101642,281656,332660,417674,063349,550349,550349,550349,550336,569333,344333,344333,344333,344333,344333,344333,344333,344333,3440334,834334,834334,844334,844118,910164,573202,313
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
96,803
102,084
48,559
140,498
137,307
52,911
7,799
7,241
7,248
7,549
9,350
8,468
8,648
8,708
8,793
8,468
9,808
7,992
7,023
6,103
6,1037,0237,9929,8088,4688,7938,7088,6488,4689,3507,5497,2487,2417,79952,911137,307140,49848,559102,08496,80300000000000000000000000000
> Total Liabilities 
9,371
17,114
5,523
14,192
14,192
56,993
56,993
0
13,292
50,349
29,852
85,084
147,155
26,632
57,995
52,988
45,104
87,988
168,555
306,215
190,191
210,712
502,046
673,899
637,026
710,553
639,034
1,006,146
1,270,281
1,144,364
1,482,749
1,805,907
1,707,999
1,780,445
1,588,782
1,537,475
1,549,407
1,669,226
1,899,831
1,706,357
1,703,816
1,386,188
1,395,573
1,369,239
1,357,818
1,327,836
1,327,8361,357,8181,369,2391,395,5731,386,1881,703,8161,706,3571,899,8311,669,2261,549,4071,537,4751,588,7821,780,4451,707,9991,805,9071,482,7491,144,3641,270,2811,006,146639,034710,553637,026673,899502,046210,712190,191306,215168,55587,98845,10452,98857,99526,632147,15585,08429,85250,34913,292056,99356,99314,19214,1925,52317,1149,371
   > Total Current Liabilities 
9,371
17,114
5,523
14,192
14,192
56,993
56,993
0
13,292
50,349
29,852
85,084
147,155
26,632
28,313
23,928
16,667
60,174
49,212
189,278
75,660
98,587
373,300
233,496
181,333
235,937
128,704
444,443
568,760
428,107
773,129
465,706
375,642
461,522
266,386
229,570
104,290
225,077
466,398
286,440
312,388
329,863
318,651
346,429
366,454
361,172
361,172366,454346,429318,651329,863312,388286,440466,398225,077104,290229,570266,386461,522375,642465,706773,129428,107568,760444,443128,704235,937181,333233,496373,30098,58775,660189,27849,21260,17416,66723,92828,31326,632147,15585,08429,85250,34913,292056,99356,99314,19214,1925,52317,1149,371
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
107,783
106,741
21,964
0
0
202,619
207,685
214,318
220,910
226,693
226,828
226,965
226,965226,828226,693220,910214,318207,685202,6190021,964106,741107,7830000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
45,854
149,862
25,428
164,359
131,096
136,170
48,656
7,487
7,354
6,161
3,379
4,659
4,633
122,583
366,333
1,304
1,231
89
267
8,045
25,059
13,497
13,49725,0598,045267891,2311,304366,333122,5834,6334,6593,3796,1617,3547,48748,656136,170131,096164,35925,428149,86245,854000000000000000000000000
       Other Current Liabilities 
9,371
17,114
5,523
14,192
14,192
56,993
56,993
0
13,292
50,349
29,852
85,084
147,155
26,632
28,313
23,928
16,667
60,174
49,212
189,278
75,660
98,587
373,300
94,609
41,782
33,806
2,294
739
697
62,911
94,746
109,505
95,702
80,383
38,845
40,661
49,938
40,886
50,166
52,299
60,989
74,048
63,093
89,896
3,407
3,548
3,5483,40789,89663,09374,04860,98952,29950,16640,88649,93840,66138,84580,38395,702109,50594,74662,9116977392,29433,80641,78294,609373,30098,58775,660189,27849,21260,17416,66723,92828,31326,632147,15585,08429,85250,34913,292056,99356,99314,19214,1925,52317,1149,371
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
510,330
561,703
701,521
716,257
709,620
1,340,201
1,332,357
1,318,923
1,322,396
1,307,905
1,445,117
1,444,149
1,433,433
1,419,917
1,391,428
1,056,325
1,076,922
1,022,810
991,364
966,664
966,664991,3641,022,8101,076,9221,056,3251,391,4281,419,9171,433,4331,444,1491,445,1171,307,9051,322,3961,318,9231,332,3571,340,201709,620716,257701,521561,703510,33000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
29,682
29,060
28,437
27,814
119,343
116,937
114,531
112,125
128,746
440,403
455,693
474,616
476,794
528,628
668,908
684,106
677,936
771,911
764,549
751,599
755,557
741,552
879,251
878,772
868,545
857,402
834,484
506,520
0
487,110
0
0
00487,1100506,520834,484857,402868,545878,772879,251741,552755,557751,599764,549771,911677,936684,106668,908528,628476,794474,616455,693440,403128,746112,125114,531116,937119,34327,81428,43729,06029,68200000000000000
> Total Stockholder Equity
1,173,721
930,444
769,145
814,450
814,450
657,725
657,725
657,725
1,973,734
1,830,347
1,782,991
1,677,829
1,513,740
4,899,805
4,868,284
4,820,182
4,797,793
4,713,788
4,676,490
4,568,546
4,460,784
4,292,250
4,416,891
4,539,844
4,208,302
4,080,486
4,057,176
3,982,052
3,664,014
3,586,396
3,517,790
3,553,154
3,510,186
3,415,878
3,426,175
3,331,144
3,257,799
2,941,504
2,835,373
2,768,437
2,746,252
2,714,924
2,644,657
2,646,828
2,643,932
2,566,086
2,566,0862,643,9322,646,8282,644,6572,714,9242,746,2522,768,4372,835,3732,941,5043,257,7993,331,1443,426,1753,415,8783,510,1863,553,1543,517,7903,586,3963,664,0143,982,0524,057,1764,080,4864,208,3024,539,8444,416,8914,292,2504,460,7844,568,5464,676,4904,713,7884,797,7934,820,1824,868,2844,899,8051,513,7401,677,8291,782,9911,830,3471,973,734657,725657,725657,725814,450814,450769,145930,4441,173,721
   Common Stock
1,930,600
1,930,600
1,931,250
1,941,170
1,941,170
1,941,720
1,941,720
0
2,165,500
2,165,770
2,167,940
2,167,940
2,170,505
2,472,930
2,477,327
2,485,278
2,490,323
2,499,418
2,501,958
2,501,958
2,503,008
2,503,388
2,503,833
2,508,153
2,510,470
2,513,800
2,521,770
2,521,770
2,521,830
2,521,900
2,521,980
2,522,190
2,522,200
2,522,230
2,522,430
2,523,040
2,523,110
2,523,270
2,523,560
2,523,630
2,523,740
2,525,530
0
2,529,350
0
0
002,529,35002,525,5302,523,7402,523,6302,523,5602,523,2702,523,1102,523,0402,522,4302,522,2302,522,2002,522,1902,521,9802,521,9002,521,8302,521,7702,521,7702,513,8002,510,4702,508,1532,503,8332,503,3882,503,0082,501,9582,501,9582,499,4182,490,3232,485,2782,477,3272,472,9302,170,5052,167,9402,167,9402,165,7702,165,50001,941,7201,941,7201,941,1701,941,1701,931,2501,930,6001,930,600
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000000000000000
   Capital Surplus 0000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-10,843
-10,563
-9,203
-8,891
-8,185
-8,253
-11,763
-10,867
-13,092
-15,166
-17,602
-17,370
-20,198
-20,261
-35,970
-27,258
-22,366
-12,738
-15,834
0
9,034
0
0
009,0340-15,834-12,738-22,366-27,258-35,970-20,261-20,198-17,370-17,602-15,166-13,092-10,867-11,763-8,253-8,185-8,891-9,203-10,563-10,84300000000000000000000000



Balance Sheet

Currency in TWD. All numbers in thousands.




Cash Flow

Currency in TWD. All numbers in thousands.




Income Statement

Currency in TWD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue491,777
Cost of Revenue-266,544
Gross Profit225,233225,233
 
Operating Income (+$)
Gross Profit225,233
Operating Expense-658,008
Operating Income-166,231-432,775
 
Operating Expense (+$)
Research Development294,278
Selling General Administrative97,186
Selling And Marketing Expenses0
Operating Expense658,008391,464
 
Net Interest Income (+$)
Interest Income8,364
Interest Expense-14,813
Other Finance Cost-0
Net Interest Income-6,449
 
Pretax Income (+$)
Operating Income-166,231
Net Interest Income-6,449
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-194,810-166,231
EBIT - interestExpense = -14,813
-194,810
-179,997
Interest Expense14,813
Earnings Before Interest and Taxes (EBIT)0-179,997
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-194,810
Tax Provision-0
Net Income From Continuing Ops-194,810-194,810
Net Income-194,810
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net06,449
 

Technical Analysis of TaiMed Biologics
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of TaiMed Biologics. The general trend of TaiMed Biologics is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine TaiMed Biologics's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of TaiMed Biologics.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 84.70 < 85.70 < 87.50.

The bearish price targets are: 80.60 > 80.60 > 76.30.

Tweet this
TaiMed Biologics Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of TaiMed Biologics. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

TaiMed Biologics Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of TaiMed Biologics. The current macd is -2.57875421.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the TaiMed Biologics price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for TaiMed Biologics. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the TaiMed Biologics price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
TaiMed Biologics Daily Moving Average Convergence/Divergence (MACD) ChartTaiMed Biologics Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of TaiMed Biologics. The current adx is 20.82.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell TaiMed Biologics shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
TaiMed Biologics Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of TaiMed Biologics. The current sar is 90.43.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
TaiMed Biologics Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of TaiMed Biologics. The current rsi is 38.60. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
TaiMed Biologics Daily Relative Strength Index (RSI) ChartTaiMed Biologics Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of TaiMed Biologics. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the TaiMed Biologics price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
TaiMed Biologics Daily Stochastic Oscillator ChartTaiMed Biologics Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of TaiMed Biologics. The current cci is -108.03214754.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
TaiMed Biologics Daily Commodity Channel Index (CCI) ChartTaiMed Biologics Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of TaiMed Biologics. The current cmo is -27.30949204.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
TaiMed Biologics Daily Chande Momentum Oscillator (CMO) ChartTaiMed Biologics Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of TaiMed Biologics. The current willr is -91.875.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
TaiMed Biologics Daily Williams %R ChartTaiMed Biologics Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of TaiMed Biologics.

TaiMed Biologics Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of TaiMed Biologics. The current atr is 2.84421843.

TaiMed Biologics Daily Average True Range (ATR) ChartTaiMed Biologics Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of TaiMed Biologics. The current obv is 133,799,587.

TaiMed Biologics Daily On-Balance Volume (OBV) ChartTaiMed Biologics Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of TaiMed Biologics. The current mfi is 36.49.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
TaiMed Biologics Daily Money Flow Index (MFI) ChartTaiMed Biologics Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for TaiMed Biologics.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-01MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-25STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-20ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-23BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-20MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

TaiMed Biologics Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of TaiMed Biologics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.603
Ma 20Greater thanMa 5088.410
Ma 50Greater thanMa 10093.017
Ma 100Greater thanMa 20088.938
OpenGreater thanClose83.500
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of TaiMed Biologics with someone you think should read this too:
  • Are you bullish or bearish on TaiMed Biologics? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about TaiMed Biologics? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about TaiMed Biologics

I send you an email if I find something interesting about TaiMed Biologics.


Comments

How you think about this?

Leave a comment

Stay informed about TaiMed Biologics.

Receive notifications about TaiMed Biologics in your mailbox!